Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07098338 · ClinicalTrials.gov registry record · Phase 2
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 278
- Enrollment target
- 20
- Study locations
NCT07098338 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 278 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT07098338, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 278 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
Conditions Studied
Interventions
- DRUG Ramucirumab
- DRUG Rilvegostomig
- DRUG Dato-DXd
Study Locations (20)
Other
- Research Site - Nedlands
- Research Site - Woodville
- Research Site - Changsha
- Research Site - Chengdu
- Research Site - Deyang
- Research Site - Dongguan
- Research Site - Fuzhou
- Research Site - Guangzhou
- Research Site - Guangzhou
- Research Site - Hangzhou
- Research Site - Hefei
- Research Site - Linyi
- Research Site - Mianyang
California
- Research Site - Santa Monica
- Research Site - Santa Rosa
Georgia
- Research Site - Atlanta
Maryland
- Research Site - Baltimore
Texas
- Research Site - Houston
Virginia
- Research Site - Fairfax
Ontario
- Research Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2029-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07098338
The ClinicalTrials.gov registry entry for NCT07098338 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (58% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Ramucirumab is the first listed.
NCT07098338 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07098338 about?
NCT07098338 is a clinical study titled "A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)". This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of variou...
What is the current status of trial NCT07098338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2025-08-07. Estimated completion is 2029-04-06.
What conditions does trial NCT07098338 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT07098338?
The interventions under investigation include: Ramucirumab (DRUG), Rilvegostomig (DRUG), Dato-DXd (DRUG).
Who is sponsoring clinical trial NCT07098338?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07098338 being conducted?
This trial has 20 study locations across California, Georgia, Maryland, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.